Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Roeselare – page 79

2 207 clinical trials in Roeselare, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Roeselare at a glance
2 207
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 207 trials in Roeselare

Open in trial search

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Colorectal adenocarcinoma

Not yet recruiting

A Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Verastem Inc.

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Safety and Immune Response of GBS-NN/NN2 and Tdap Vaccines in Preventing Group B Strep Infection in Healthy Women Aged 18-49

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GBS-NN
  • Sponsor:Minervax ApS

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Hopital Erasme

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Interstitial lung disease+1

Not yet recruiting

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Roeselare

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on bladder cancer, lung cancer, and various blood cancers. Studies evaluate novel combination therapies and targeted treatments.

  • Non-muscle invasive bladder cancer treatment
  • Advanced non-small cell lung cancer therapies
  • Multiple myeloma and leukemia interventions

Research includes innovative immunotherapy combinations and precision medicine approaches.

02 Metabolic Disorders

Clinical investigations targeting hypertriglyceridemia and obesity-related conditions, with emphasis on novel therapeutic approaches.

  • Weight management therapies
  • Type 2 diabetes treatments
  • Lipid disorder interventions

Studies focus on developing safer and more effective treatments for metabolic conditions.

03 Neurological Conditions

Studies examining treatments for Alzheimer's disease and multiple sclerosis, with particular attention to innovative therapeutic approaches.

  • Alzheimer's-related psychosis management
  • Relapsing-remitting multiple sclerosis therapies
  • Neurological disease modifications

Research aims to improve quality of life and disease management for patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.